Last reviewed · How we verify
Sulfadoxine pyrimethamine (SP)
Sulfadoxine pyrimethamine (SP) is a combination antibiotic that works by inhibiting the growth of bacteria by interfering with their ability to synthesize folic acid.
Sulfadoxine pyrimethamine (SP) is a combination antibiotic that works by inhibiting the growth of bacteria by interfering with their ability to synthesize folic acid. Used for Malaria prophylaxis and treatment.
At a glance
| Generic name | Sulfadoxine pyrimethamine (SP) |
|---|---|
| Also known as | G-COSPE |
| Sponsor | Menzies School of Health Research |
| Drug class | Antibiotic |
| Target | Dihydropteroate synthase, Dihydrofolate reductase |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Sulfadoxine is a sulfonamide antibiotic that inhibits dihydropteroate synthase, an enzyme involved in the synthesis of tetrahydrofolic acid. Pyrimethamine is a dihydrofolate reductase inhibitor that also interferes with the synthesis of tetrahydrofolic acid. This dual mechanism of action makes SP effective against a wide range of bacteria.
Approved indications
- Malaria prophylaxis and treatment
Common side effects
- Nausea
- Vomiting
- Diarrhea
Key clinical trials
- MULTIple Doses of IPTi Proposal: a Lifesaving High Yield Intervention
- Perennial Malaria Chemoprevention in the Malaria Vaccine Era (PHASE4)
- Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi (PHASE4)
- Optimal Chemopreventive Regimens to Prevent Malaria and Improve Birth Outcomes in Uganda (PHASE3)
- Sulfadoxine-pyrimethamine Plus Dihydroartemisinin-piperaquine for Intermittent Preventive Treatment in Pregnancy (PHASE3)
- Gestational Sulfadoxine-pyrimethamine and Azithromycin Treatment to Prevent Preterm Birth (PHASE3)
- Parasite Clearance and Protection from Infection (PCPI) in Cameroon (PHASE3)
- Parasite Clearance and Protection From Infection (PCPI) in Zambia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sulfadoxine pyrimethamine (SP) CI brief — competitive landscape report
- Sulfadoxine pyrimethamine (SP) updates RSS · CI watch RSS
- Menzies School of Health Research portfolio CI